Proteasome 20S β5i subunit antibody | knockout validation | Enzo Life Science BML-PW8845-0025

This is a knockout-validated antibody summary, based on the publication "A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Mouse monoclonal IgG1

Company: Enzo Life Science

Antibody: Proteasome 20S β5i subunit

Catalog number: BML-PW8845-0025

Summary: Mouse monoclonal IgG1 against recombinant human proteasome subunit β5i. Reacts with human and rat. Suitable for western blot and immunohistochemistry.

Validation Method

Western blot

Sample

Control and β5i-knock out SK-Mel5 and UACC257 melanoma cell lines. Total cell lysate was extracted using RIPA buffer.

Blocking agent

5% milk for 1 hour block at room temperature.

Primary incubation

Using the manufacturer’s s recommended dilution overnight at 4°C.

Secondary incubation

HRP-conjugated antibodies.

Figure

Immunoblot of the indicated proteins in control and β5i-knock out in SK-Mel5 and UACC257 melanoma cell lines using a CRISPR approach. Please see Figure 5a in the article [1].

Clone note

The same clone (LMP7-1) is sold as LifeSpan Biosciences LS-C343797; Enzo Life Sciences BML-PW8845-0025.

References
  1. Chang A, Dao T, Gejman R, Jarvis C, Scott A, Dubrovsky L, et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest. 2017;127:2705-2718 pubmed publisher